ALX Oncology Holdings Inc.

NASDAQ:ALXO

Biotechnology

Healthcare
$0.97 -2.12%

-$0.03 today

Market cap
$134.14M
Beta
0.45
P/E (TTM)
-0.9
EPS (TTM)
-$1.64
52W Low $0.40High $2.66

Volume 0.56M

Average 1.07M

ALXO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

ALX Oncology Holdings Inc.NASDAQ: ALXO

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $5.36M fell 32.4% year over year, behind the -23.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.

Context

  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -8.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.36M-0.3% QoQ
Last fiscal yearDec 2025
$23.85M-8.6% YoY
LTMMar 2026
$21.28M-23.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.4%-100.0%-67.6 pp
1 year-8.6%-100.0%-91.4 pp
3-year CAGR-6.3%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
23.85M USD
Year-over-year change
-8.6%
4-year CAGR
+0.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ALXO compares with its peers on the latest reported figures

  • ALXO's LTM Mar 2026 selling, general & admin of $21.28M is the lowest of the 8 companies compared; the peer median is $37.85M.
  • Its year-over-year change of -23.4% is the lowest of 8, against a peer median of +0.6%.
  • Over three fiscal years its annual growth of -6.3% compares with a peer median of +10.0%.
ALXO Competitors Peer median
Selling, General & Admin for ALXO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCYCBicycle Therapeutics plcLTM Mar 2026$76.67M +0.6%+17.4%120.8%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$75.77M +15.3%+15.9%72.2%
STOKStoke Therapeutics, Inc.LTM Mar 2026$71.21M +35.2%+19.9%222.0%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$37.85M +8.5%+10.0%88.1%
ANNXAnnexon, Inc.LTM Mar 2026$32.75M -0.8%+0.8%—
NKTXNkarta, Inc.LTM Mar 2026$25.06M -19.7%+4.0%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$23.71M -4.5%+3.4%10537.3%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M -23.4%-6.3%—
Peer median (excluding ALXO) $37.85M+0.6%+10.0%120.8%

Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development60.17M98.4M141.8M116.37M77M
Selling, General & Admin23.39M29.04M28.48M26.09M23.85M
Operating Expenses83.56M127.44M170.28M142.47M104.02M
Depreciation & Amortization51K342K836K872K706K
EBITDA(83.42M)(122.84M)(158.4M)(132.25M)(99.39M)
EBITDA Margin—————
Operating Income(83.56M)(127.44M)(170.28M)(142.47M)(104.02M)
Operating Margin—————
Interest Income914.28M10.65M9.37M3.96M
Interest Expense13K238K1.57M1.73M1.6M
Other Income / Expenses71K4.02M9.47M7.62M2.33M
Income Before Tax(83.48M)(123.42M)(160.81M)(134.85M)(101.7M)
Pre-Tax Margin—————
Income Tax Expense(21K)64K000
Net Income(83.46M)(123.48M)(160.81M)(134.85M)(101.7M)
Net Margin—————
EPS (Basic)(2.07)(3.03)(3.74)(2.58)(1.90)
EPS (Diluted)(2.07)(3.03)(3.74)(2.58)(1.90)
Weighted Avg Shares40.31M40.7M42.99M52.17M53.66M
Weighted Avg Shares (Diluted)40.31M40.7M42.99M52.17M53.66M

ALX Oncology Holdings Inc.

NASDAQ:ALXO

Intrinsic Alpha fair value

Locked

Current Price

$0.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.